Abstract 424P
Background
Paraneoplastic leucomoid reaction (PLR) is well described entity where white blood cell (WBC) count increase ≥50000/mm3 in association with malignancy.It is known to be predictive of poor prognosis.Recent research works have demonstrated that there are relationships between PLR activated by intratumoral production of granulocyte colony stimulatory factor (G-CSF), the RAS/RAF/MEK pathway and tumorogenesis. It may even seen before diagnosis of malignancy. It is too important to understand the cause of high WBC count to start specific proper treatment or change treatment protocol because many clinicians delayed to start treatment that harmful for patients.
Methods
The study was an observational study. Study period was January 2022 to June 2022.
Results
Of total 350 patients, PLR was found in only 24 (6.86%).Age range of patients were from 32 years to 85 years and average was 60 years. Among them, carcinoma lung 6(25%) where 4(66.66%) patients were metastatic to liver and 2(33.33%) patient had localized disease; carcinoma gall bladder 4(16.66%) where 4(100%) had metastasis to liver; carcinoma unknown primary 4(16.66%); carcinoma buccal mucosa 4(16.66%); carcinoma cervix 2(8.33%); metastatic prostate cancer 2(8.33%) and carcinoma urinary bladder 2(8.33%).Infections were ruled out methodically by culture and sensitivity of blood, urine, bone marrow but none showed any growth. 14(58.33%) patients were on specific treatment and 41.67%) patients were on supportive management after PLR develop. 23(95.83%) patients developed PLR after diagnosis of cancer or during cancer treatment or many days thereafter. Only 1(4.17%) patient developed PLR before diagnosis of malignancy. WBC count ≥50000/mm3 were found in 23(95.83%) and only 1(4.67%) patient had 45000/ mm3. Neutrophil count ≥90% were documented in 14(58.33%) patients and ≥85% in 10(41.67%). Platelet count were found high in 12(50%). Bone marrow examinations16(66.67%) showed Neutrophilic leucocytosis in 14(87.5%) patients.Death from development of PLR from 4 days to 240 days and average time of death was documented within 72 days.
Conclusions
In developing countries, patients were underwent investigations repeatedly for a long period for PLR that delayed diagnosis, ultimately delayed treatment and we lost patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06